Amilpar - Relevant Fact

RIO DE JANEIRO, Dec. 21 Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR ; Reuters: AMIL3.SA), the largest managed care organization in Brazil, in accordance with article 157, paragraph 4, of Law 6,404/76 (Brazilian Corporate Law) and CVM Instruction nº 358/02, and in addition to the Relevant Facts released on November 19, 2009, December 2 and 9, 2009, informs its shareholders and the market that its subsidiary Amil Assistencia Medica Internacional Ltda. will proceed only with the mandatory public offer for the acquisition of shares issued by Medial Saude S.A. due to the change of control of this company (Tag Along) and will not, at the moment, promote public offer for the following purposes (a) exit of the Bovespa's Novo Mercado and (b) cancellation of the register of public company (delisting) of Medial Saude S.A.

Amilpar will keep the market and its shareholders informed about the conclusion of the above mentioned offer.

To access the Relevant Fact visit our website at www.amilpar.com.br/ir

IR Contact ---------- Erwin Kleuser ------------- Investor Relations Officer -------------------------- Phone: +55 (21) 3805-1155 ------------------------- [email protected] ------------------ www.amilpar.com.br/ir ---------------------

SOURCE Amilpar

Latest Press Release on Drug News

41st International Conference on Drug Discovery and Drug delivery system

On behalf of the organizing committee its great pleasure to invite to all attendees of the "41st International Conference on Drug Discovery and Drug Delivery System" taking place on November...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: S...